| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sona Nanotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.23 |
| 52 Week High | CA$0.41 |
| 52 Week Low | CA$0.11 |
| Beta | -1.59 |
| 1 Month Change | -24.17% |
| 3 Month Change | -5.21% |
| 1 Year Change | 26.88% |
| 3 Year Change | -81.04% |
| 5 Year Change | 51.67% |
| Change since IPO | 16.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| SNAN.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -10.8% | -2.4% | -0.9% |
| 1Y | 26.9% | 8.3% | 25.8% |
Return vs Industry: SNAN.F exceeded the US Life Sciences industry which returned 8.3% over the past year.
Return vs Market: SNAN.F exceeded the US Market which returned 25.8% over the past year.
Price Volatility
| SNAN.F volatility | |
|---|---|
| SNAN.F Average Weekly Movement | 23.4% |
| Life Sciences Industry Average Movement | 6.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SNAN.F's share price has been volatile over the past 3 months.
Volatility Over Time: SNAN.F's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | David Regan | www.sonanano.com |
Sona Nanotech Inc. operates as a nanotechnology life sciences company. It develops targeted hyperthermia therapy for cancer treatment; and nanomedical therapy for the treatment of colorectal cancer. The company also develops gold nanoparticle products; lateral flow assay rapid tests; bovine TB tests; and concussion screening tests.
Sona Nanotech Inc. Fundamentals Summary
| SNAN.F fundamental statistics | |
|---|---|
| Market cap | US$23.21m |
| Earnings (TTM) | -US$2.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.7x
P/E RatioIs SNAN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNAN.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.86m |
| Earnings | -CA$2.86m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 44.6% |
How did SNAN.F perform over the long term?
See historical performance and comparison